38213-69-3
中文名稱
雙(麥芽醇)氧釩(IV)
英文名稱
Bis(maltolato)oxovanadium(IV)
CAS
38213-69-3
分子式
C12H10O7V
分子量
317.15
MOL 文件
38213-69-3.mol
更新日期
2026/07/23 09:43:54
38213-69-3 結構式
基本信息
中文別名
雙(麥芽醇)氧釩(IV) 英文別名
BMOVBIS(MALTOLATO)OXOVANADIUM
BIS(MALTOLATO)OXOVANADIUM(IV)
oxovanadium(2+) bis(2-methyl-4-oxo-4H-pyran-3-olate)
(SP-5-31)-Bis[3-(hydroxy-κO)-2-Methyl-4H-pyran-4-onato-κO4]oxovanadiuM
Vanadium,bis[3-(hydroxy-kO)-2-methyl-4H-pyran-4-onato-kO4]oxo-, (SP-5-31)-
所屬類別
原料藥物理化學性質
熔點>300°C (dec.)
儲存條件Refrigerator
溶解度DMSO（少許）、甲醇（少許）、水（少許）
形態(tài)粉末
顏色黃色到灰色到棕色
InChI1S/2C6H5O3.O.V/c2*1-4-6(8)5(7)2-3-9-4;;/h2*2-3H,1H3;;/q2*-1;;+2
InChIKeyNGWOELASSYWDDT-UHFFFAOYSA-N
SMILES[V+2]=O.O2[C-](C(=O)C(=O)C=C2)C.O1[C-](C(=O)C(=O)C=C1)C
LogP0.079 (est)
雙(麥芽醇)氧釩(IV)價格(試劑級)
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/07/06 | S2255 | 雙(麥芽醇)氧釩(IV) BMOV | 38213-69-3 | 25mg | 1280.48元 |
| 2026/06/05 | HY-118567 | 雙(麥芽醇)氧釩(IV) Bis(maltolato)oxovanadium(IV) | 38213-69-3 | 5 mg | 400元 |
| 2026/06/05 | HY-118567 | 雙(麥芽醇)氧釩(IV) Bis(maltolato)oxovanadium(IV) | 38213-69-3 | 10 mM * 1 mLin DMSO | 440元 |
常見問題列表
生物活性
BMOV (Bis maltolato oxovanadium, Bis(maltolato)oxovanadium (IV))是一種有效的口服釩復合物，具有抗糖尿病特性和模仿胰島素的作用。BMOV被證明可改善糖尿病模型的心臟功能障礙。靶點
IC50: 126 nM (HCPTPA), 109 nM (PTP1B), 26 nM (HPTPβ) and 201 nM (SHP2)
體外研究
Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells.
體內研究
Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice.
| Animal Model: | C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) |
| Dosage: | 0.75-3.0 mmol |
| Administration: | Intraperitoneal injection; twice weekly; for 6 weeks |
| Result: | Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |